Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03588923
Other study ID # SHC005-I-03
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date July 7, 2018
Est. completion date August 10, 2018

Study information

Verified date August 2018
Source Nanjing Sanhome Pharmaceutical, Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antiviral activity of single and multiple ascending doses of SH229 in patients with chronic hepatitis C Virus infection.


Description:

A total of 30 evaluable patients will be enrolled in this study. The planned dose levels are 400, 600, and 800 mg.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date August 10, 2018
Est. primary completion date August 10, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Subjects are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose;

- 18-65 years of age;

- Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive, and a body weight =50 kg for males and =45 kg for females;

- No previous treatment with any direct-acting antiviral (DAA) drugs for HCV, such as Boceprevir, Telaprevir, Simeprevir, Sofosbuvir, Daclatasvir, Asunaprevir;

- No antiviral treatment such as immune modulators, thymosin or other immune stimulating factors, interferon, or Chinese herbs in the past 6 months;

- HCV RNA =10*5 IU/mL at screening (Roche COBAS Taqman);

- Chronic genotype 1-6 HCV Infection;

- Serum ALT =10 times ULN;

- FibroScan score =17.5kPa within 6 months before screening or at screening, or absence of cirrhosis within 12 months before screening;

- Subjects are capable of understanding and complying with the protocol and have signed the informed consent form.

Exclusion Criteria:

- Smoke more than 5 cigarettes per day within three months prior to screening;

- Subjects allergic to the study drug (including its excipients) or subjects who are prone to allergies;

- History of drug and/or alcohol abuse (alcohol consumption exceeding 14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine);

- Blood donation or massive blood loss (> 450 mL) within three months prior to screening;

- History of any non-HCV liver diseases, including but not limited to hemochromatosis, primary biliary cirrhosis, Wilson's disease, autoimmune hepatitis, drug or alcoholic hepatitis, non-alcoholic steatohepatitis, etc.;

- Subjects with dysphagia or with any gastrointestinal disorders (or postoperative conditions) that may affect the study drug absorption;

- Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers;

- Use of any drugs that alter liver enzyme activity within 28 days prior to screening;

- Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening;

- Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the disposition of the study drug within 2 weeks prior to screening;

- Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone;

- Subjects with major changes in diet or exercise habits recently;

- Participation in other clinical trials within three months prior to enrollment;

- Electrocardiogram abnormalities with clinical significance;

- Laboratory tests with clinical significance or other clinical findings that indicate clinically significant diseases not associated with HCV infection (including but not limited to gastrointestinal, renal, hepatic, neurologic, hematological, endocrine, pulmonary, psychiatric, cardiovascular diseases);

- Pregnant or lactating women;

- Creatinine clearance = 60 mL/min;

- Evidence of co-infection with HBV, HIV, or syphilis;

- Child-Pugh Grade B or C;

- Clinically significant hepatic decompensation including but not limited to, hepatic encephalopathy, hepatocellular carcinoma, variceal bleeding, ascites, etc.;

- Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours prior to dosing;

- Use of products containing alcohol within 24 hours prior to dosing;

- Subjects with urine drug screening test positive, or with history of drug abuse in the past 5 years;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SH229
tablet, oral, 400 mg once daily for 3 days
Placebos
tablet, oral, once daily for 3 days
SH229
tablet, oral, 600 mg once daily for 3 days
Placebos
tablet, oral, once daily for 3 days
SH229
tablet, oral, 800 mg once daily for 3 days
Placebos
tablet, oral, once daily for 3 days

Locations

Country Name City State
China Phase I Clinical Trial Unit, The First Hospital of Jilin University Changchun Jilin

Sponsors (1)

Lead Sponsor Collaborator
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events up to Day 10
Primary Antiviral effects of SH229, as measured by HCV RNA levels up to Day 10
Secondary Time to peak plasma concentration(Tmax) up to Day 10
Secondary Peak plasma concentration(Cmax) up to Day 10
Secondary Half-life time(t1/2) up to Day 10
Secondary Area under the plasma concentration versus time curve(AUC) up to Day 10
See also
  Status Clinical Trial Phase
Completed NCT03674125 - Evaluation of Safety, Tolerability, and Immunogenicity Study of GLS-6150 in Healthy Volunteers and in Persons Previously Treated for Hepatitis C Virus Infection Phase 1
Completed NCT00978497 - Safety, Tolerability, and Antiviral Activity of ANA598 Administered in Combination With Pegylated Interferon and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection Phase 2
Completed NCT00170131 - MMF Influence on HCV Viral Evolution After Liver Transplantation Phase 4
Completed NCT04008927 - A Community-based Intervention Among Active Drug Users in Montpellier N/A
Active, not recruiting NCT04044586 - HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
Completed NCT01958281 - Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency Phase 2
Completed NCT02533427 - Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl Estradiol Phase 1
Completed NCT02783976 - Sovaldi-based Regimens in Patients in Mexico With Chronic Hepatitis C Virus Infection in Clinical Practice
Withdrawn NCT04309734 - Study of AT-777 in Healthy Subjects and AT-777 in Combination With AT-527 in HCV-Infected Subjects Phase 1/Phase 2
Completed NCT01965535 - Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection Phase 2
Completed NCT00768690 - A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 Phase 1
Completed NCT00743795 - Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection Phase 2
Withdrawn NCT04235049 - Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE) Phase 4
Terminated NCT00401947 - A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ACH-0137171 in Participants With Chronic Hepatitis C Infection Phase 2
Completed NCT00959699 - A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) Phase 2
Completed NCT00623649 - Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection Phase 1
Completed NCT00221624 - Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients Phase 3
Completed NCT04134767 - Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE) N/A
Completed NCT02402452 - Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment Phase 1
Completed NCT00909636 - A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of the ABT-333 Tablet Phase 1